Free Trial
NASDAQ:PYXS

Pyxis Oncology Q2 2023 Earnings Report

Pyxis Oncology logo
$1.16 -0.03 (-2.52%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.18 +0.02 (+1.72%)
As of 07/11/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Pyxis Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pyxis Oncology Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Conference Call Date
Friday, August 11, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Pyxis Oncology's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Pyxis Oncology Earnings Headlines

Pyxis Oncology Inc News (PYXS) - Investing.com
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS) is a precision oncology company dedicated to advancing personalized cancer treatments through biomarker-driven insights. The company specializes in the discovery, development and commercialization of diagnostic assays that profile the tumor microenvironment and genomic alterations associated with immuno-oncology and targeted therapies. Utilizing proprietary ex vivo functional assays and next-generation sequencing platforms, Pyxis Oncology identifies determinants of drug response and resistance to inform clinical trial design and therapeutic strategies.

Pyxis Oncology’s product portfolio includes tissue-based and liquid biopsy assays designed to measure immune cell functionality, cytokine release and tumor-specific genetic mutations. Key services encompass functional immunoprofiling to evaluate patient response to immunotherapies, comprehensive genomic profiling to detect actionable mutations, and companion diagnostic development in collaboration with biopharmaceutical partners. The company’s integrated approach leverages high-throughput biomarker screening and data analytics to accelerate go-to-market timelines for novel oncology therapeutics.

Founded in 2020 and headquartered in the Boston metropolitan area, Pyxis Oncology operates state-of-the-art laboratories in North America and maintains partnerships across Europe and Asia to support global drug development programs. Leveraging a multidisciplinary team of immunologists, molecular biologists and bioinformaticians, the company aims to bridge the gap between laboratory research and clinical application, empowering oncologists with deeper insights into treatment mechanisms.

Under the leadership of CEO David J. Jung, M.D., M.B.A., and Chief Scientific Officer Audrey Kunzelmann, Ph.D., Pyxis Oncology has rapidly expanded its footprint in the oncology diagnostics space. The company is backed by a consortium of healthcare investors and collaborates with leading academic centers to validate its assays and drive innovation in precision immuno-oncology.

View Pyxis Oncology Profile

More Earnings Resources from MarketBeat